Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.

about

Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.

Item

http://www.wikidata.org/entity/Q55020070

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Optimizing the treatment of me ...... : a Latin America perspective.

@en

Optimizing the treatment of me ...... : a Latin America perspective.

@nl

type

Item

label

Optimizing the treatment of me ...... : a Latin America perspective.

@en

Optimizing the treatment of me ...... : a Latin America perspective.

@nl

prefLabel

Optimizing the treatment of me ...... : a Latin America perspective.

@en

Optimizing the treatment of me ...... : a Latin America perspective.

@nl

P1476

Optimizing the treatment of me ...... r: a Latin America perspective

@en

P2093

Carlos Alberto Vargas Báez

http://www.w3.org/2001/XMLSchema#string

Carlos Humberto Martínez

http://www.w3.org/2001/XMLSchema#string

Carlos Palazzo

http://www.w3.org/2001/XMLSchema#string

Diogo Assed Bastos

http://www.w3.org/2001/XMLSchema#string

Fabio Augusto Schutz

http://www.w3.org/2001/XMLSchema#string

Juan Pablo Sade

http://www.w3.org/2001/XMLSchema#string

Martin Greco

http://www.w3.org/2001/XMLSchema#string

Miguel Ángel Álvarez Avitia

http://www.w3.org/2001/XMLSchema#string

Narciso Hernández Toriz

http://www.w3.org/2001/XMLSchema#string

Patricia Isabel Bernal Trujillo

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Contemporary approaches for imaging skeletal metastasis

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola

P2888

s12032-018-1105-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-018-1105-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lucas Nogueira

Neal D Shore

P5008

ScienceSource

P577

2018-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101628707

http://www.w3.org/2001/XMLSchema#string

P698

29556815

http://www.w3.org/2001/XMLSchema#string

P921

castration-resistant prostatic neoplasm

P932

5859699

http://www.w3.org/2001/XMLSchema#string